Market Tracker

09/29 5:57am ET

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX)

3.90
Delayed Data
As of Sep 28
 +0.05 / +1.30%
Today’s Change
2.40
Today|||52-Week Range
5.88
+1.30%
Year-to-Date
AcelRx (ACRX) Initiates Phase III IAP312 Study on Zalviso
Sep 28 / Zacks.com - Paid Partner Content
Company News for September 16, 2016
Sep 16 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close3.85
Today’s open3.91
Day’s range3.77 - 4.08
Volume763,371
Average volume (3 months)372,936
Market cap$174.5M
Dividend yield--
Data as of 09/28/2016

Growth & Valuation

Earnings growth (last year)+34.07%
Earnings growth (this year)-49.67%
Earnings growth (next 5 years)+46.60%
Revenue growth (last year)+269.24%
P/E ratioNM
Price/Sales8.89
Price/Book5.26

Competitors

 Today’s
change
Today’s
% change
PRQRProQR Therapeutics N...-0.28-3.69%
DPRXDipexium Pharmaceuti...0.000.00%
OCULOcular Therapeutix I...-0.03-0.43%
MDWDMediwound Ltd-0.01-0.12%
Data as of 09/28/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)-$0.24
Annual revenue (last year)$19.3M
Annual profit (last year)-$24.4M
Net profit margin-126.66%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Director
Howard B. Rosen
CFO &
Head-Business Development
Timothy E. Morris
Corporate headquarters
Redwood City, California

Forecasts